Eintrag weiter verarbeiten
Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , |
| In: | Journal of Clinical Oncology, 23, 2005, 34, S. 8853-8862 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Mendrzyk, Frank Radlwimmer, Bernhard Joos, Stefan Kokocinski, Felix Benner, Axel Stange, Daniel E. Neben, Kai Fiegler, Heike Carter, Nigel P. Reifenberger, Guido Korshunov, Andrey Lichter, Peter Mendrzyk, Frank Radlwimmer, Bernhard Joos, Stefan Kokocinski, Felix Benner, Axel Stange, Daniel E. Neben, Kai Fiegler, Heike Carter, Nigel P. Reifenberger, Guido Korshunov, Andrey Lichter, Peter |
|---|---|
| author |
Mendrzyk, Frank Radlwimmer, Bernhard Joos, Stefan Kokocinski, Felix Benner, Axel Stange, Daniel E. Neben, Kai Fiegler, Heike Carter, Nigel P. Reifenberger, Guido Korshunov, Andrey Lichter, Peter |
| spellingShingle |
Mendrzyk, Frank Radlwimmer, Bernhard Joos, Stefan Kokocinski, Felix Benner, Axel Stange, Daniel E. Neben, Kai Fiegler, Heike Carter, Nigel P. Reifenberger, Guido Korshunov, Andrey Lichter, Peter Journal of Clinical Oncology Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma Cancer Research Oncology |
| author_sort |
mendrzyk, frank |
| spelling |
Mendrzyk, Frank Radlwimmer, Bernhard Joos, Stefan Kokocinski, Felix Benner, Axel Stange, Daniel E. Neben, Kai Fiegler, Heike Carter, Nigel P. Reifenberger, Guido Korshunov, Andrey Lichter, Peter 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2005.02.8589 <jats:sec><jats:title>Purpose</jats:title><jats:p>Medulloblastoma is the most common malignant brain tumor in children. Despite multimodal aggressive treatment, nearly half of the patients die as a result of this tumor. Identification of molecular markers for prognosis and development of novel pathogenesis-based therapies depends crucially on a better understanding of medulloblastoma pathomechanisms.</jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p>We performed genome-wide analysis of DNA copy number imbalances in 47 medulloblastomas using comparative genomic hybridization to large insert DNA microarrays (matrix-CGH). The expression of selected candidate genes identified by matrix-CGH was analyzed immunohistochemically on tissue microarrays representing medulloblastomas from 189 clinically well-documented patients. To identify novel prognostic markers, genomic findings and protein expression data were correlated to patient survival.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Matrix-CGH analysis revealed frequent DNA copy number alterations of several novel candidate regions. Among these, gains at 17q23.2-qter (P < .01) and losses at 17p13.1 to 17p13.3 (P = .04) were significantly correlated to poor prognosis. Within 17q23.2-qter and 7q21.2, two of the most frequently gained chromosomal regions, confined amplicons were identified that contained the PPM1D and CDK6 genes, respectively. Immunohistochemistry revealed strong expression of PPM1D in 148 (88%) of 168 and CDK6 in 50 (30%) of 169 medulloblastomas. Overexpression of CDK6 correlated significantly with poor prognosis (P < .01) and represented an independent prognostic marker of overall survival on multivariate analysis (P = .02).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>We identified CDK6 as a novel molecular marker that can be determined by immunohistochemistry on routinely processed tissue specimens and may facilitate the prognostic assessment of medulloblastoma patients. Furthermore, increased protein-levels of PPM1D and CDK6 may link the TP53 and RB1 tumor suppressor pathways to medulloblastoma pathomechanisms.</jats:p></jats:sec> Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2005.02.8589 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNS4wMi44NTg5 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNS4wMi44NTg5 |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Society of Clinical Oncology (ASCO), 2005 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2005 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
mendrzyk2005genomicandproteinexpressionprofilingidentifiescdk6asnovelindependentprognosticmarkerinmedulloblastoma |
| publishDateSort |
2005 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma |
| title_unstemmed |
Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma |
| title_full |
Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma |
| title_fullStr |
Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma |
| title_full_unstemmed |
Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma |
| title_short |
Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma |
| title_sort |
genomic and protein expression profiling identifies cdk6 as novel independent prognostic marker in medulloblastoma |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2005.02.8589 |
| publishDate |
2005 |
| physical |
8853-8862 |
| description |
<jats:sec><jats:title>Purpose</jats:title><jats:p>Medulloblastoma is the most common malignant brain tumor in children. Despite multimodal aggressive treatment, nearly half of the patients die as a result of this tumor. Identification of molecular markers for prognosis and development of novel pathogenesis-based therapies depends crucially on a better understanding of medulloblastoma pathomechanisms.</jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p>We performed genome-wide analysis of DNA copy number imbalances in 47 medulloblastomas using comparative genomic hybridization to large insert DNA microarrays (matrix-CGH). The expression of selected candidate genes identified by matrix-CGH was analyzed immunohistochemically on tissue microarrays representing medulloblastomas from 189 clinically well-documented patients. To identify novel prognostic markers, genomic findings and protein expression data were correlated to patient survival.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Matrix-CGH analysis revealed frequent DNA copy number alterations of several novel candidate regions. Among these, gains at 17q23.2-qter (P < .01) and losses at 17p13.1 to 17p13.3 (P = .04) were significantly correlated to poor prognosis. Within 17q23.2-qter and 7q21.2, two of the most frequently gained chromosomal regions, confined amplicons were identified that contained the PPM1D and CDK6 genes, respectively. Immunohistochemistry revealed strong expression of PPM1D in 148 (88%) of 168 and CDK6 in 50 (30%) of 169 medulloblastomas. Overexpression of CDK6 correlated significantly with poor prognosis (P < .01) and represented an independent prognostic marker of overall survival on multivariate analysis (P = .02).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>We identified CDK6 as a novel molecular marker that can be determined by immunohistochemistry on routinely processed tissue specimens and may facilitate the prognostic assessment of medulloblastoma patients. Furthermore, increased protein-levels of PPM1D and CDK6 may link the TP53 and RB1 tumor suppressor pathways to medulloblastoma pathomechanisms.</jats:p></jats:sec> |
| container_issue |
34 |
| container_start_page |
8853 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
23 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347421441785869 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:55:01.511Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Genomic+and+Protein+Expression+Profiling+Identifies+CDK6+As+Novel+Independent+Prognostic+Marker+in+Medulloblastoma&rft.date=2005-12-01&genre=article&issn=1527-7755&volume=23&issue=34&spage=8853&epage=8862&pages=8853-8862&jtitle=Journal+of+Clinical+Oncology&atitle=Genomic+and+Protein+Expression+Profiling+Identifies+CDK6+As+Novel+Independent+Prognostic+Marker+in+Medulloblastoma&aulast=Lichter&aufirst=Peter&rft_id=info%3Adoi%2F10.1200%2Fjco.2005.02.8589&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347421441785869 |
| author | Mendrzyk, Frank, Radlwimmer, Bernhard, Joos, Stefan, Kokocinski, Felix, Benner, Axel, Stange, Daniel E., Neben, Kai, Fiegler, Heike, Carter, Nigel P., Reifenberger, Guido, Korshunov, Andrey, Lichter, Peter |
| author_facet | Mendrzyk, Frank, Radlwimmer, Bernhard, Joos, Stefan, Kokocinski, Felix, Benner, Axel, Stange, Daniel E., Neben, Kai, Fiegler, Heike, Carter, Nigel P., Reifenberger, Guido, Korshunov, Andrey, Lichter, Peter, Mendrzyk, Frank, Radlwimmer, Bernhard, Joos, Stefan, Kokocinski, Felix, Benner, Axel, Stange, Daniel E., Neben, Kai, Fiegler, Heike, Carter, Nigel P., Reifenberger, Guido, Korshunov, Andrey, Lichter, Peter |
| author_sort | mendrzyk, frank |
| container_issue | 34 |
| container_start_page | 8853 |
| container_title | Journal of Clinical Oncology |
| container_volume | 23 |
| description | <jats:sec><jats:title>Purpose</jats:title><jats:p>Medulloblastoma is the most common malignant brain tumor in children. Despite multimodal aggressive treatment, nearly half of the patients die as a result of this tumor. Identification of molecular markers for prognosis and development of novel pathogenesis-based therapies depends crucially on a better understanding of medulloblastoma pathomechanisms.</jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p>We performed genome-wide analysis of DNA copy number imbalances in 47 medulloblastomas using comparative genomic hybridization to large insert DNA microarrays (matrix-CGH). The expression of selected candidate genes identified by matrix-CGH was analyzed immunohistochemically on tissue microarrays representing medulloblastomas from 189 clinically well-documented patients. To identify novel prognostic markers, genomic findings and protein expression data were correlated to patient survival.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Matrix-CGH analysis revealed frequent DNA copy number alterations of several novel candidate regions. Among these, gains at 17q23.2-qter (P < .01) and losses at 17p13.1 to 17p13.3 (P = .04) were significantly correlated to poor prognosis. Within 17q23.2-qter and 7q21.2, two of the most frequently gained chromosomal regions, confined amplicons were identified that contained the PPM1D and CDK6 genes, respectively. Immunohistochemistry revealed strong expression of PPM1D in 148 (88%) of 168 and CDK6 in 50 (30%) of 169 medulloblastomas. Overexpression of CDK6 correlated significantly with poor prognosis (P < .01) and represented an independent prognostic marker of overall survival on multivariate analysis (P = .02).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>We identified CDK6 as a novel molecular marker that can be determined by immunohistochemistry on routinely processed tissue specimens and may facilitate the prognostic assessment of medulloblastoma patients. Furthermore, increased protein-levels of PPM1D and CDK6 may link the TP53 and RB1 tumor suppressor pathways to medulloblastoma pathomechanisms.</jats:p></jats:sec> |
| doi_str_mv | 10.1200/jco.2005.02.8589 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNS4wMi44NTg5 |
| imprint | American Society of Clinical Oncology (ASCO), 2005 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2005 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T17:55:01.511Z |
| match_str | mendrzyk2005genomicandproteinexpressionprofilingidentifiescdk6asnovelindependentprognosticmarkerinmedulloblastoma |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 8853-8862 |
| publishDate | 2005 |
| publishDateSort | 2005 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Mendrzyk, Frank Radlwimmer, Bernhard Joos, Stefan Kokocinski, Felix Benner, Axel Stange, Daniel E. Neben, Kai Fiegler, Heike Carter, Nigel P. Reifenberger, Guido Korshunov, Andrey Lichter, Peter 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2005.02.8589 <jats:sec><jats:title>Purpose</jats:title><jats:p>Medulloblastoma is the most common malignant brain tumor in children. Despite multimodal aggressive treatment, nearly half of the patients die as a result of this tumor. Identification of molecular markers for prognosis and development of novel pathogenesis-based therapies depends crucially on a better understanding of medulloblastoma pathomechanisms.</jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p>We performed genome-wide analysis of DNA copy number imbalances in 47 medulloblastomas using comparative genomic hybridization to large insert DNA microarrays (matrix-CGH). The expression of selected candidate genes identified by matrix-CGH was analyzed immunohistochemically on tissue microarrays representing medulloblastomas from 189 clinically well-documented patients. To identify novel prognostic markers, genomic findings and protein expression data were correlated to patient survival.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Matrix-CGH analysis revealed frequent DNA copy number alterations of several novel candidate regions. Among these, gains at 17q23.2-qter (P < .01) and losses at 17p13.1 to 17p13.3 (P = .04) were significantly correlated to poor prognosis. Within 17q23.2-qter and 7q21.2, two of the most frequently gained chromosomal regions, confined amplicons were identified that contained the PPM1D and CDK6 genes, respectively. Immunohistochemistry revealed strong expression of PPM1D in 148 (88%) of 168 and CDK6 in 50 (30%) of 169 medulloblastomas. Overexpression of CDK6 correlated significantly with poor prognosis (P < .01) and represented an independent prognostic marker of overall survival on multivariate analysis (P = .02).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>We identified CDK6 as a novel molecular marker that can be determined by immunohistochemistry on routinely processed tissue specimens and may facilitate the prognostic assessment of medulloblastoma patients. Furthermore, increased protein-levels of PPM1D and CDK6 may link the TP53 and RB1 tumor suppressor pathways to medulloblastoma pathomechanisms.</jats:p></jats:sec> Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma Journal of Clinical Oncology |
| spellingShingle | Mendrzyk, Frank, Radlwimmer, Bernhard, Joos, Stefan, Kokocinski, Felix, Benner, Axel, Stange, Daniel E., Neben, Kai, Fiegler, Heike, Carter, Nigel P., Reifenberger, Guido, Korshunov, Andrey, Lichter, Peter, Journal of Clinical Oncology, Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma, Cancer Research, Oncology |
| title | Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma |
| title_full | Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma |
| title_fullStr | Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma |
| title_full_unstemmed | Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma |
| title_short | Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma |
| title_sort | genomic and protein expression profiling identifies cdk6 as novel independent prognostic marker in medulloblastoma |
| title_unstemmed | Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2005.02.8589 |